News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Orexigen Therapeutics, Inc. (OREX) to Present CONTRAVE(TM) Clinical Summary at Center for Business Intelligence's 3rd Annual Obesity Drug Development Summit


7/27/2007 11:13:32 AM

SAN DIEGO & ARLINGTON, Va.--(BUSINESS WIRE)--Orexigen™ Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, will be presenting today at The Center for Business Intelligence’s (CBI) 3rd Annual Obesity Drug Development Summit. Ronald Landbloom, M.D., Vice President of Medical and Regulatory Affairs at Orexigen, will discuss a summary of clinical trial results to date on Contrave™, the Company’s lead obesity drug candidate.

Read at BioSpace.com

comments powered by Disqus
   
Obesity

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES